Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Assertio Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ASRT NEW YORK, Feb. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Assertio Holdings, Inc. (NASDAQ: ASRT) between March 9, 2023...

Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition Second Quarter Net Product Sales Increase 13% Year-Over-Year, Generates $18.6 Million in Cash Flow from Operations Acquisition Expected to be Significantly Accretive to Adjusted EPS in 2024 LAKE...